Replies to post #237840 on Biotech Values

[DewDiligence]

ZY -75%/AH on shocking business update:

https://www.globenewswire.com/news-release/2021/08/03/2274125/0/en/Zymergen-Provides-Business-Update.html

Zymergen recently became aware of issues with its commercial product pipeline that will impact the Company’s delivery timeline and revenue projections. Accordingly, the Company no longer expects product revenue in 2021, and expects product revenue to be immaterial in 2022.

ZY went public only three months ago (#msg-163354411); I commented then on how vague the corporate mission statement was. Maybe that was a red flag.